Advancements in artificial intelligence are accelerating drug discovery, diagnostics, and patient care within biotech and medicine. Pleno has launched early access to its multiomics biomarker detection platform, leveraging 'hypercoding' technology for expansive genomic and proteomic profiling at lower costs. Zephyr AI's acquisition of Aster Insights significantly enhances its real-world oncology datasets, enabling improved clinical decision-making and trial design. Additional developments include AI tools for early cancer detection from Johns Hopkins and deep learning applications in medical imaging and predictive modeling. Collaborations between AI and healthcare companies underscore the ongoing integration of computational methods into life sciences.